Edition:
India

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

8.15USD
1:30am IST
Change (% chg)

$-0.26 (-3.09%)
Prev Close
$8.41
Open
$8.45
Day's High
$8.45
Day's Low
$8.03
Volume
448,731
Avg. Vol
132,322
52-wk High
$14.00
52-wk Low
$4.10

Select another date:

Tue, Jun 5 2018

Florida doctor admits taking kickbacks from Insys, others

June 4 A Florida doctor has admitted, as part of a plea deal, that he received kickbacks from Insys Therapeutics Inc in exchange for writing prescriptions for a powerful fentanyl-based pain medicine.

Minnesota sues opioid maker Insys over improper drug marketing

Minnesota on Wednesday became the latest state to sue Insys Therapeutics Inc , accusing the drugmaker of illegally marketing a powerful fentanyl-based pain medicine, while a former employee pleaded guilty in New Jersey over bribing doctors to prescribe the drug.

UPDATE 3-Minnesota sues opioid maker Insys over improper drug marketing

May 30 Minnesota on Wednesday became the latest state to sue Insys Therapeutics Inc, accusing the drugmaker of illegally marketing a powerful fentanyl-based pain medicine, while a former employee pleaded guilty in New Jersey over bribing doctors to prescribe the drug.

Minnesota sues opioid manufacturer Insys over drug marketing

May 30 The state of Minnesota on Wednesday sued Insys Therapeutics Inc, accusing the pharmaceutical manufacturer of illegally marketing a powerful fentanyl-based pain medicine intended for cancer patients for other uses.

U.S. joins whistleblower case against Insys over kickbacks

The U.S. Department of Justice has joined whistleblower litigation accusing Insys Therapeutics Inc of trying to generate more profit by paying kickbacks to doctors to prescribe powerful opioid medications.

U.S. joins lawsuits against opioid maker Insys over kickback scheme

May 14 The U.S. Department of Justice has joined lawsuits accusing Insys Therapeutics Inc of paying kickbacks to doctors to prescribe a powerful opioid medication, in an effort to generate more profit.

BRIEF-Insys Therapeutics Announces Exclusive License Partnership To Commercialize Subsys In Middle East

* INSYS THERAPEUTICS ANNOUNCES EXCLUSIVE LICENSE PARTNERSHIP WITH LUNATUS TO COMMERCIALIZE SUBSYS® (FENTANYL SUBLINGUAL SPRAY) IN THE MIDDLE EAST

BRIEF-Insys Therapeutics Reports First Quarter 2018 Results

* Q1 EARNINGS PER SHARE VIEW $-0.18 -- THOMSON REUTERS I/B/E/S

Ex-Insys employee in U.S. opioid case sentenced to home confinement

April 23 A former Insys Therapeutics Inc sales representative was sentenced on Monday to six months of home confinement after admitting that she participated in a scheme to pay kickbacks to two Alabama doctors to prescribe a fentanyl-based medication.

BRIEF-Insys Therapeutics To Advance Clinical Research Of Dronabinol Inhalation Using Novel Breath-Actuated Device

* INSYS THERAPEUTICS TO ADVANCE CLINICAL RESEARCH OF DRONABINOL INHALATION USING NOVEL BREATH-ACTUATED DEVICE

Select another date: